The Oncology Bet Is Already Paying Off For Pfizer

Benzinga11-14 08:23

With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483629278?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T17My1Xowf0ctud5YtvJcg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/eeac3cc78e2352f7fe351184c2b1bf99","is_english":true,"pubTime":"2024-11-14 08:23","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483629278","market":"us","top_or_hot":-1,"title":"The Oncology Bet Is Already Paying Off For Pfizer","media":"Benzinga","content":"<div>\n<p>With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14%...</p>\n\n<a href=\"https://finance.yahoo.com/news/oncology-bet-already-paying-off-002315025.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Oncology Bet Is Already Paying Off For Pfizer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Oncology Bet Is Already Paying Off For Pfizer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 08:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oncology-bet-already-paying-off-002315025.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14%...</p>\n\n<a href=\"https://finance.yahoo.com/news/oncology-bet-already-paying-off-002315025.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1791710582.SGD","symbol_name":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","start_time":0,"source_url":"https://finance.yahoo.com/news/oncology-bet-already-paying-off-002315025.html","article_id":"2483629278","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T17My1Xowf0ctud5YtvJcg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/eeac3cc78e2352f7fe351184c2b1bf99"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483629278","pubTimestamp":1731543795,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc  reported its third quarter revenue grew14% on an operational basisdue to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc  posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs. But, even with Covid-19 still lingering in the air, Moderna has also focused on harnessing the power of mRNA to make biotech history by revolutionizing cancer treatment. However, there is also a significant advancement in early screening and even possible prevention when it comes to the cancer front. For example, their much smaller peer,Mainz Biomed  just announced a new collaboration agreement aimed at developing and potentially commercializing its next generation colorectal cancer screening product.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4566":"资本集团","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","PFE":"辉瑞","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4535":"淡马锡持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0061474960.USD":"天利环球焦点基金AU Acc","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","MYNZ":"Mainz Biomed B.V.","BK4585":"ETF&股票定投概念","SG9999001176.USD":"United Global Healthcare Acc USD","BK4551":"寇图资本持仓","BK4581":"高盛持仓","LU1923622291.USD":"Natixis Thematics Safety R/A USD","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","MRNA":"Moderna, Inc.","LU1923622614.USD":"Natixis Thematics Meta R/A USD","TMO":"赛默飞世尔","LU0557290698.USD":"施罗德环球可持续增长基金","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","GRO":"Brazil Potash Corp."},"translate_title":"辉瑞的肿瘤赌注已经获得回报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMO":1,"PFE":1,"MYNZ":1,"MRNA":1,"GRO":1},"content_text":"With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs. But, even with Covid-19 still lingering in the air, Moderna has also focused on harnessing the power of mRNA to make biotech history by revolutionizing cancer treatment. However, there is also a significant advancement in early screening and even possible prevention when it comes to the cancer front. For example, their much smaller peer, Mainz Biomed (NASDAQ: MYNZ) just announced a new collaboration agreement aimed at developing and potentially commercializing its next generation colorectal cancer screening product.\nMainz Biomed’s next generation CRC screening product is coming to redefine standards.\nMainz Biomed is a molecular genetics diagnostic company specialized in the early detection of cancer. This week, it announced it entered into a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation, a leading provider of life sciences solutions and services.\nWith the power of Thermo Fisher’s powerful technologies, instrumentation and information translation systems, Mainz Biomed will be empowered to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are raising the bar when it comes to early cancer detection. With U.S. and European clinical trials of its flagship non-invasive test, Mainz Biomed promises to redefine standards in cancer screening. With ColoAlert, Mainz Biomed not only offers the early detection of colorectal cancer but also detects advanced adenomas which are a known cancer precursor, therefore, opening the doors its peers didn’t dare to tackle, the ones of cancer prevention. \nPfizer topped estimates and hiked its full year guidance. \nCancer drugs brought in $854 million to Pfizer’s revenue table, including $409 million from a targeted treatment for bladder cancer called Padcev and $268 million from lymphoma-targeting Adectris. Good results provided some much-needed good news for Pfizer CEO Albert Bourla, who is facing new pressure from activist investor Starboard Value.\nFor the third quarter, Pfizer reported overall revenue of  $17.7 billion.\nModerna continues to focus on developing cancer treatment along with lowering costs.\nBack in September, Moderna revealed its plan to cut its research and development budget by $1.1 billion over the next three years while it aims to get FDA approval for 10 products like cancer treatments and vaccines. During the latest earnings call, Moderna CEO Stéphane Bancel was pleased with the cost efficiency achieved during the quarter, with the progress being even better than planned. For the third quarter, Moderna reported revenue of $1.86 billion, smashing LSEG’s consensus estimate of $1.25 billion. While Pfizer already counts on oncology for boosting sales, Moderna’s sales are still made by the Covid shot, along with RSV one that brought  $10 million in U.S. sales after gaining approval in May. However, with 45 products in development powered by its messenger RNA platform, Moderna expects to bring 10 of them to the market over the next three years.\nDISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.\nThis article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.\nUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.\nGet the latest stock analysis from Benzinga?\n\nPFIZER (PFE): Free Stock Analysis Report\n\nThis article The Oncology Bet Is Already Paying Off For Pfizer originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483629278"}